

# ALZHEIMER'S DISEASE

## FACTS AND FIGURES

### SYMPTOMS INCLUDE<sup>1</sup>

- MEMORY LOSS
- DIFFICULTY COMPLETING DAILY TASKS
- CHALLENGES IN PLANNING OR SOLVING PROBLEMS
- CONFUSION WITH TIME OR PLACE
- CHANGES IN MOOD AND PERSONALITY
- MISPLACING THINGS
- DECREASED OR POOR JUDGEMENT



Alzheimer's disease and other dementias, 2019<sup>2</sup>

7<sup>th</sup> leading cause of death globally

2<sup>nd</sup> leading cause of death in high-income countries

COVID-19

Apolipoprotein E  $e^4$  allele associated with Alzheimer's disease is linked with an increased susceptibility to SARS-CoV-2 infection and COVID-19 mortality<sup>3,4</sup>

AD is the most common form of dementia, contributes to 60-70% of cases<sup>5</sup>



Brain changes in AD may begin 20 years or more before symptoms appear<sup>6</sup>

Women are disproportionately affected. Globally, 65% of deaths from Alzheimer's and other dementias are women<sup>2</sup>



AD and other dementias resulted in 25.3 million global DALYs in 2019<sup>7</sup>



1 out of 9 people aged 65+ has Alzheimer's dementia in the US<sup>6</sup>

Total direct and indirect cost of care for AD and other dementias globally is estimated to rise to \$9.12 trillion by 2050<sup>8</sup>

Alzheimer's disease & other dementias deaths per 100,000 2019<sup>9</sup>

\*AD – Alzheimer's disease  
DALYs – Disability adjusted life years

**Disclaimer:**  
This publication on the Alzheimer's disease pathway framework was updated on 14.06.2023. It cannot be taken as a recommendation for the readers, especially not as a guideline for treatment, and it is not a medical document. There is no guarantee for completeness or global correctness, the various pain points, solutions, and statistical data are examples only. Sources are multiple, such as public statistics, expert opinions, open innovation workshops, research, own data and many more (see references).  
The products and features mentioned may not be available in all countries and their future availability cannot be guaranteed. Some products mentioned are planned and under development.

1. Alzheimer's Association. 10 Early Signs and Symptoms of Alzheimer's. Retrieved April 22, 2023, from [https://www.alz.org/alzheimers-dementia/10\\_signs](https://www.alz.org/alzheimers-dementia/10_signs)
2. World Health Organization. (2020, December 9). The top 10 causes of death. Retrieved April 22, 2023, from <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
3. Kurki, S.N., Kantonen, J., Kaiuola, K. et al. (2021). APOE  $\epsilon 4$  associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. *Acta Neuropathol Commun*, 9(1), 199. <https://doi.org/10.1186/s40478-021-01302-7>
4. Xia, X., Wang, Y. & Zheng, J. COVID-19 and Alzheimer's disease: how one crisis worsens the other. *Translational Neurodegeneration*. 10, 15 (2021). <https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-021-00237-2>
5. World Health Organization. (2021, September 2). Dementia. Retrieved April 22, 2023, from <https://www.who.int/news-room/fact-sheets/detail/dementia>
6. Alzheimer's Association. (2023). 2023 Alzheimer's Disease Facts and Figures. Retrieved April 22, 2023, from <https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf>
7. The Lancet. (2019). Alzheimer's disease and other dementias – Level 3 cause. Global Health Metrics. <https://www.thelancet.com/pb-assets/Lancet/gbd/summaries/diseases/alzheimers-dementias.pdf>
8. Nandi, A., Counts, N., Chen, S., Seligman, B., Tortorice, D., Vigo, D., & Bloom, D. E. (2022). Global and regional projections of the economic burden of Alzheimer's disease and related Dementias from 2019 to 2050: A value of Statistical Life Approach. *EClinicalMedicine*, 51, 101580. <https://doi.org/10.1016/j.eclim.2022.101580>
9. GBD compare. Institute for Health Metrics and Evaluation. (n.d.). Retrieved April 22, 2023, from <https://vizhub.healthdata.org/gbd-compare/>



An extensive research-based analysis from 40+ scientific articles and journals in combination with hospital workflow experience allowed the identification of pain points and solutions.

These solutions were proposed based on AI, IoMT, AR/VR, biosensors, nanorobotics and smart wearable technologies.

THROUGH THIS CAREPLAN WE  
HIGHLIGHT DATA FROM  
A COLLECTION OF

74  
pain points

98  
solutions

connected to  
different stakeholders

## Solution categories

- Existing in healthcare sector
- Ongoing research in healthcare
- Futuristic solution (may or may not be implemented)

## Disclaimer:

This publication on the Alzheimer's disease pathway framework was updated on 14.06.2023. It cannot be taken as a recommendation for the readers, especially not as a guideline for treatment, and it is not a medical document. There is no guarantee for completeness or global correctness, the various pain points, solutions, and statistical data are examples only. Sources are multiple, such as public statistics, expert opinions, open innovation workshops, research, own data and many more (see references). The products and features mentioned may not be available in all countries and their future availability cannot be guaranteed. Some products mentioned are planned and under development.

